Interdisciplinary consensus statement on indication and application of a hydrogel spacer for prostate radiotherapy based on experience in more than 250 patients

Arndt-Christian Müller¹, Johannes Mischinger², Theodor Klotz³, Bernd Gagel⁴, Gregor Habi⁵, Gencay Hatiboglu⁶, Michael Pinkawa⁷

¹ Department of Radiation Oncology, Eberhard Karls University, Tübingen, Germany
² Department of Urology, Eberhard Karls University, Tübingen, Germany
³ Department of Urology, Hospital Weiden, Weiden, Germany
⁴ Department of Radiation Oncology, Hospital Weiden, Weiden, Germany
⁵ Department of Radiation Oncology, Technical University Munich, Munich, Germany
⁶ Department of Urology, University of Heidelberg, Heidelberg, Germany
⁷ Department of Radiation Oncology, RWTH Aachen University, Aachen, Germany

Research article

Background. The aim of the study was to reach a consensus on indication and application of a hydrogel spacer based on multicentre experience and give new users important information to shorten the learning curve for this innovative technique.

Methods. The interdisciplinary meeting was attended by radiation oncologists and urologists, each with experience of 23 – 138 hydrogel injections (SpaceOAR®) in prostate cancer patients before dose-escalated radiotherapy. User experience was discussed and questions were defined to comprise practical information relevant for successful hydrogel injection and treatment. Answers to the defined key questions were generated. Hydrogel-associated side effects were collected to estimate the percentage, treatment and prognosis of potential risks.

Results. The main indication for hydrogel application was dose-escalated radiotherapy for histologically confirmed low or intermediate risk prostate cancer. It was not recommended in locally advanced prostate cancer. The injection or implantation was performed under transrectal ultrasound guidance via the transperineal approach after prior hydrodissection. The rate of injection-related G2-toxicity was 2% (n = 5) in a total of 258 hydrogel applications. The most frequent complication (n = 4) was rectal wall penetration, diagnosed at different intervals after hydrogel injection and treated conservatively.

Conclusions. A consensus was reached on the application of a hydrogel spacer. Current experience demonstrated feasibility, which could promote initiation of this method in more centres to reduce radiation-related gastrointestinal toxicity of dose-escalated IGRT. However, a very low rate of a potential serious adverse event could not be excluded. Therefore, the application should carefully be discussed with the patient and be balanced against potential benefits.

Key words: prostate cancer; hydrogel spacer; dose-escalated radiotherapy; proctitis; toxicity
Background

Dose escalated intensity-modulated radiation treatment (IMRT with radiation doses ≥ 76 Gy) is a highly effective, curative treatment option for localized prostate cancer. Biochemical control is directly related to radiation dose with a dose effect per each additional Gy. For example, escalation from 70 to 80 Gy is connected with a 15% increase in PSA control. This dose effect is described for all risk groups. However, an increased radiation dose is also associated with rising levels of grade ≥ 2 acute and chronic toxicity. Lower gastrointestinal toxicity rates can result from smaller posterior safety margins or even no safety margins, potentially compromising local tumour control.

A novel method to reduce rectal toxicity during dose-escalated IMRT is the insertion of a hydrogel spacer between the Denonvilliers’ fascia and anterior rectal wall to separate these structures. The created space generates a distance of 10 – 15 mm between both organs. Recent studies unequivocally demonstrated a significant reduction in high-dose areas on the anterior rectal wall. As expected, better rectal sparing from higher radiation doses was associated with only mild toxicity from the dose-escalated treatment.

The application technique, dosimetric studies and some early toxicity data, as mentioned above, were all published within the last two years. However, despite rising numbers of hydrogel injections, reports on practical aspects or pitfalls of hydrogel application as well as frequency and management of side effects of the administration were not or were only provided for single cases. Therefore, the first consensus meeting was held in July 2013 to discuss this practical issue and to generate answers for users on the indication, application and management of side effects of a hydrogel spacer for dose-escalated radiotherapy. Thereafter, toxicity data of the injection technique was collected from > 250 patients of four centres to better balance the benefit and potential risks of this new method.

The aim of this consensus report is to offer new users of this technique easy access to relevant information on practical application and patient management to shorten the learning curve and to carefully balance potential benefits against potential risks of this technique.

Patients and methods

The interdisciplinary meeting was attended by radiation oncologists and urologists, each with experience of 23 – 138 hydrogel injections (SpaceOAR®) in prostate cancer patients before dose-escalated IMRT. In the first part of the meeting, user experiences were discussed and questions were defined to comprise practical information relevant for successful gel injection and treatment. In the second part, answers to the defined key questions were developed. Prospective data from the multi-institutional clinical trial, prospective institutional data (German Clinical Trials Register DRKS00003273) and data collected retrospectively from patient files were considered in this interdisciplinary process to evaluate hydrogel application in current practice. The prospective studies were approved by each institution’s ethics committee.

After the meeting, participants were asked to state the incidence of side effects to better balance risks and beneficial effects. Finally, the statement was revised and consented. Recommendations derived from prospective studies were indicated as level of evidence (LOE) 2a (evidence obtained from prospective studies were indicated as LOE 4). After discussing the intended analysis of retrospectively collected data (n = 196) the institutional review board (Ethics Committee of the University of Tübingen) had no objections (266/2015BO2). Patients gave informed consent to standardized data documentation and evaluation of treatment related toxicity.

The SpaceOAR® System (resulting in 10 mL hydrogel) is FDA cleared and CE Mark approved, and commercially available in the US and most countries of Western Europe.

Results

The following key questions were developed with regard to practical aspects of hydrogel application and patient management:
1. Indication: what criteria are required to recommend the injection of a hydrogel spacer in an individual patient?
2. Injection technique: how should the injection be optimally applied?
3. Potential toxicity: which side effects could theoretically occur?
4. Prophylaxis: are prophylactic procedures reasonable?
5. Actual toxicity: what is the current grade 2 or higher toxicity rate of hydrogel injection measured according to CTC v 4.0.
6. Treatment of side effects: how should side effects be treated?
7. Absolute exclusion criteria: what are absolute exclusion criteria for the injection?
8. Relative exclusion criteria: what are relative exclusion criteria for the injection?
9. Special aspects of radiation treatment planning:
   Which aspects of radiation treatment planning should be considered?

The following key answers were developed:

**Indication**

A hydrogel spacer can be considered for dose-escalated radiotherapy (radiation doses ≥ 76 Gy in conventional 1.8 – 2.0 Gy fractions) for histologically confirmed low or intermediate risk prostate cancer (LOE 2a).

A hydrogel spacer can be considered for dose-escalated radiotherapy (radiation doses ≥ 76 Gy in conventional 1.8 – 2.0 Gy fractions) for histologically confirmed prostate cancer with any localized disease (LOE 4). The risk of a microscopic T3 stage with risk of adhesions potentially impairing the hydrosissection should be considered.

Following hydrogel injection, other forms of dose-escalated radiotherapy as hypofractionated radiotherapy, particle beam radiotherapy or brachytherapy were also carried out.

**Injection technique**

Hydrogel injection can be performed under local (possibly additional sedation), spinal or general anaesthesia. Additional procedures that are planned at the same time (i.e. brachytherapy, marker implantation etc.) determine the selected anaesthesia and should be performed in advance or a few days later since hydrogel injection might worsen visibility by air contamination. For preparation of the patient see also 3. Prophylaxis. Generally, the patient is placed in the lithotomy position. The injection is performed transperineally under transrectal ultrasound (TRUS) guidance using a linear side-fire TRUS probe and a stand-off balloon to optimize visibility. A stepper unit stabilizes the probe, so that both hands are free for the procedure. The transperineal route is well known for procedures such as prostate biopsies, fiducial placement or prostate brachytherapy.

All centres involved in this consensus used the hydrosissection technique before spacer injection to separate Denonvilliers’ fascia and the anterior rectal wall. This fluid-mediated tissue separation technique is also used in other settings like cataract surgery and carpal tunnel syndrome treatment. In short, an 18 gauge needle is inserted 1 – 2 cm above the patient’s anus through his perineum. The needle is advanced either parallel to the probe or slightly angled towards the prostate apex. The correct needle position is below the prostatic apex in midaxial and midsagittal position of prostate (so called midgland position). Lowering the probe before hydrosissection might facilitate the procedure. Hydrosissection is performed with 10 – 20 ml of saline or lidocaine (as local anaesthesia) diluted in saline. A slow injection of the fluid is necessary to ensure later a symmetric distribution of the spacer. Only in case of a successful hydrosissection, the hydrogel can be applied.
Hydrogel is formed during the simultaneous injection i.e. mixing of the precursor (polyethylene glycol powder) and accelerator solutions (diluent). The solutions are mixed as they pass through a Y-connector prior to passing through the injection needle. Both solutions polymerise to a soft PEG-based gel within 10 seconds. An injection of 10 mL hydrogel results in a separation of about 9 – 10 mm between the prostate and rectal wall (Figure 1). The injection procedure can be completed within a few minutes.

Potential toxicity
Depending on the type of and experience with anaesthesia, patients might experience pain and discomfort during needle insertion and hydrogel injection. After spacer injection, patients may feel discomfort and rectal tenesmus. Data on pain frequency and pain intensity after injection was not routinely collected. Therefore, only retrospective data on pain management indicating the use of ampyrone sulfonate analgesics (metamizole) for the day of the procedure and sometimes afterwards was available. During spacer injection, there might be a risk of the needle and hydrogel penetrating the rectal wall, urethra, bladder or prostate. Bleeding, necrosis or ulceration of the bladder or rectal wall may follow. Lower urinary tract symptoms or even urinary retention could result from pressure on the prostate or the bladder from the spacing gel. Local inflammation or infection is possible, as with every invasive procedure. Air or hydrogel might be potentially injected into vessels.

Prophylaxis
Anticoagulants should be discontinued. Antibiotic prophylaxis is applied in some centres with fluoroquinolones or cephalosporines. However, no infections have been diagnosed up to now, even in centres with > 100 hydrogel injections without antibiotics. A rectal enema might be used to optimize TRUS conditions during the procedure. Constipation and hard stools need to be avoided during treatment to decrease pressure on the rectal wall and a low residue diet and/or laxatives may be indicated.

Actual toxicity
Experience from all centres were participating in this consensus statement included 258 cases of hydrogel application before external beam radiotherapy for localized prostate cancer. All patients were treated with photons. Hydrogel associated complications, defined as grade 2 or higher toxicity, were experienced by 5 patients (2%). Hydrogel was injected intraprostatically in one single case. In 4 cases, rectum penetration was diagnosed at different intervals following injection. An injection into the rectal wall was observed in a single patient shortly after injection and radiotherapy was therefore started several weeks later. Two rectum penetrations were diagnosed during an external beam photon treatment after reports of passing mucous discharge. The patients were treated conservatively and radiotherapy was interrupted in one case. One patient reported increased bowel urgency 3 – 4 weeks after the end of radiotherapy before the diagnosis of a rectum penetration on proctoscopy.

All patients with the mentioned complications were followed-up with proctoscopies and/or pelvic MRI (magnetic resonance imaging). Rectal wall defects healed in all patients completely after several weeks.

Observation and treatment of side effects
Post-injection care comprises usually the first day with examination of potential urological side effects (bleeding, obstruction, pain) including the removal of a urinary catheter (if present). Side effects must be treated symptomatically. Urinary catheterization is needed in cases of urinary obstruction. Hydrogel (PEG) is not toxic or allergenic and all known injections into the prostate, bladder or rectal wall resolved without further sequelae. Patience is required as the hydrogel remains stable for three months and subsequently liquefies within 6 months. This was documented in 98% of patients (n = 43/44) in the multi-center study. Antibiotic treatment is indicated in cases of penetration, perforation or ulceration of the rectal wall and depending on the extent, patients could be kept on parenteral nutrition or a low residue diet. Radiotherapy should not be started during an infection or after inadvertent injection into the bladder or rectal wall before the healing process of a defect is complete.

Absolute exclusion criteria
(complication risk exceeds potential benefits)
locally advanced prostate cancer (space cannot be effectively created, tumour cell dissemination cannot be excluded)
active bleeding disorder or clinically significant coagulopathy

Relative exclusion criteria

anticoagulants (discontinuation usually possible)
active inflammatory or infectious disease in the perineum or injection area (prostatitis, anorectal inflammatory disease with increased risk of ulceration, fistula or bleeding such as ulcerative colitis or Crohn’s disease)
previous treatment of prostate with high risk of adhesions (high-intensity focused ultrasound, cryotherapy, radiotherapy).

Presently, very limited experience exists in hydrogel application after previous radiotherapy or high-intensity focused ultrasound. Hydrogel injection was performed without problems; however adhesions can make an injection difficult or impossible.

9. Special aspects of radiation treatment planning

Radiation treatment planning CT should start approximately five days after hydrogel injection to allow for decreasing of post-procedural swelling (and not to overestimate prostate volume). An post-injection MRI (T2-sequence sufficient without contrast media) fused to the planning CT could help to better identify the spacer (because the hydrogel is sometimes not distinguishable from the rectal wall due to same density in CT). An additional advantage of an MRI is the capability to evaluate the properness of injection. Circumferential CTV-PTV-margins depend on the verification strategy (with IGRT usually 7–10 mm, posterior if necessary less). Monitoring of the spacer volume is not necessary during radiation treatment. Stability over 3 months after injection was shown for the gel in the multicenter study.

Discussion

The most relevant practical aspects of hydrogel injection after 258 applications were summarized in this consensus statement. A detailed description of indications, prophylaxis and management of side effects should provide new users with a fast and comprehensive introduction to the successful application of this new method. After a short learning period, the procedure can be performed to a high standard, ensuring low toxicity. Most data used are derived from well-defined controlled but not randomized studies or prospective investigations, leading to Level IIA evidence for indication and application of the hydrogel spacer.

In the multi-institutional phase II trial (52 patients recruited, 49 patients after successful spacer injection), patients were informed of higher probability of grade 2+ toxicity, as no experience existed. With a carefully estimated probability of 6 – 20%, it included an injection into the rectal wall, bladder wall and urethra, ulceration and necrosis of the rectal wall, bleeding and urinary retention. Three patients who were initially treated within this study experienced procedure-related events after hydrogel injection including focal rectal necrosis due to inadvertent injection of hydrogel into the rectal wall, bladder piercing during injection with hydrogel leak into the bladder, urinary retention and a device-related proctitis. All of these events occurred during the initial experience (learning curve in the first patient cohort) and resolved completely. Adaptations of the injection procedure (side-fire TRUS probe, stepper, stand-off balloon) were conducted which facilitated handling of the needle and hydrogel insertion. A learning curve has been reported for the application and treatment with a hydrogel, again stressing several technical aspects to achieve homogenous hydrogel distribution. This report summarizes important issues that need to be considered to achieve satisfactory spacer distribution.

Radiotherapy planning should not include the usual objectives for the dose to the rectal wall. A dose of 70Gy can be allowed for 20% of the rectal wall volume according to RTOG (Radiation Therapy Oncology Group) recommendations. With a prescription dose of 76–78Gy, mean rectum volumes within the 70Gy isodose can range by about 1% with good spacer placement and adequate treatment planning.

However, the findings of this multi-institutional evaluation of spacer-related toxicity (no G3+ event) were based on conventional fractionated dose-escalated IGRT and cannot be simply adopted to other radiation treatment schedules (hypofractionation) or treatment with other ionizing radiation sources. In a study with hypofractionation using particle beam therapy (without CT-image guidance) two cases (2/92; 2%) of G3-toxicity (colostomy) occurred, a relation to the hydrogel spacer injection cannot be excluded.

Therefore, it is extremely important that patients are closely followed up at their centre after hydrogel injection. As the hydrogel is not tissue-toxic or allergenic, conservative management in case of inaccurate injection should be initiated as described above. Patience is required in case of inadvertent injection to the rectum or bladder wall, or in case...
of rectal wall penetration or ulceration. All cases in this analysis where this occurred healed without long-term sequelae. A currently published randomized trial demonstrated well toleration of spacer application (10% mild transient procedural perineal discomfort) in 149 patients suggesting safety of this method with conventional fractionated dose-escalated IGRT, too.\textsuperscript{25}

For optimized injection results, one expert in each centre was trained by another expert. The procedure was performed by only one or two experts at each centre, guaranteeing a high degree of experience. Last but not least, correct patient selection is essential. The optimal patient for this new method is at low risk of adhesions (inflammation, tumour spread due to locally advanced disease) and has a low risk of bleeding. The risk of tumour displacement by hydrodissection is very small, since prostatectomy series with limited pT3 stages reported in less than one fifth of patients an invasion and in no case a progression through the full thickness of the Denonvilliers’ fascia.\textsuperscript{26}

After successful injection, the benefit for the patients was measured by acute toxicity scores and by radiation planning parameters (dose-volume histograms). In brief, the theoretical benefit of an additional space between prostate and rectum translated into improved radiation treatment plans with approximately 10% reduction in relevant high-dose areas (dose level from 40–70Gy).\textsuperscript{8} These improved radiation treatment plans with lower rectal doses converted into reduced acute toxicity rates. Grade 2 proctitis resulting from radiotherapy was a rare event compared to standard conformal or intensity-modulated radiotherapy, for example 12.5% acute toxicity in the multicenter phase II trial\textsuperscript{19} in comparison to occasionally 50% or more in studies without a spacer.\textsuperscript{27,28} The prevention of acute proctitis with this procedure is a benefit for the patient. Further benefits for the patients are conceivable. Consequential late side effects derive from persisting acute toxicity\textsuperscript{29} and reduced acute toxicity will usually be associated with a lower risk of late toxicity. However, the evaluation of this potential long-term benefit needs longer follow-up. Another beneficial effect of improved rectum protection is the facilitation of dose escalation to the prostate. Since increased radiation doses improve outcome in the range of approximately 1.5% better biochemical control per Gy after a mean follow-up of five years\textsuperscript{1}, these dosimetric changes are relevant for improved tumour control with a lower risk of toxicity.

This spacer consensus focuses on the use of Polyethylene-glycol (PEG) hydrogel spacers in dose-escalated radiotherapy of prostate cancer. However, at least four different bio-resorbable spacer materials (PEG-hydrogel, balloon of copolymer of polylactic acid or similar poly (α-hydroxy acids), hyaluronic acid and collagen) are currently evaluated. PEG hydrogel spacers and bio-resorbable balloons have demonstrated an excellent biocompatibility profile in humans compared to other spacers made of hyaluronic acid or collagen.\textsuperscript{30} Direct comparison of PEG hydrogel spacer and bio-resorbable balloon demonstrated the following, PEG spacers were less invasive (smaller needle diameter with 1.3 vs. 2 – 3mm). The balloon spacer was superior in reducing rectum dose (-28%), but exhibited an average volume loss of > 50% during the full course of treatment (37–40 fractions), while the volume of gel spacers remained fairly constant.\textsuperscript{31}

Displacement of radiosensitive organs by spacers is not limited to primary prostate cancer alone. Further applications being investigated include treatment of recurrent prostate cancers\textsuperscript{32}, gynecological malignancies\textsuperscript{33} and esophageal gel-shifting facilitating treatment of mediastinal nodes.\textsuperscript{34} The principle to displace radiosensitive organs from high dose areas is also used in case of adhesions of small intestine and radiation targets. For such special situations are invasive surgical techniques available like laparoscopic mesh placement.\textsuperscript{35}

We conclude that hydrogel injection can be considered for dose-escalated radiotherapy. Well trained physicians, correct patient selection and knowledge of the management of potential side effects are essential for optimal application. The benefit for the patient is improved protection of the rectal wall, which is associated with low radiation related proctitis rates. This allows dose-escalation associated with improved tumour control. However, a very low rate of a potential serious adverse event cannot be excluded and should carefully be discussed with the patient and be balanced against potential benefits. The evaluation of this potential long-term benefit needs longer follow-up.

Disclosures

The consensus meeting was supported by CSDiagnostics, Neuss, Germany. Augmenix, Inc., Waltham, Massachusetts, United States is the sponsor of the multicentre-study and sponsored with
CSDiagnostics, Neuss, Germany additional hydrogels for patients treated outside the multicentre study. TK reports grants from CSDiagnostics, Neuss, Germany for another meeting.

Acknowledgment

Dr. Elizabeth Krämer performed the copyediting. We acknowledge support by Deutsche Forschungsgemeinschaft (DFG) and Open Access Publishing Fund of University of Tübingen.

References


